The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 30 December 2003, www.theannals.com, DOI 10.1345/aph.1D156.
 The Annals of Pharmacotherapy: Vol. 38, No. 2, pp. 338-341. DOI 10.1345/aph.1D156
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Abstract Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adra, M.
Right arrow Articles by Lawrence, K. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adra, M.
Right arrow Articles by Lawrence, K. R

DRUG INFORMATION ROUNDS

OBJECTIF: Evaluer le rôle du cotrimoxazole comme alternative à la vancomycine pour le traitement des infections sévères à Staphylococcus aureus.

REVUE DE LITTÉRATURE: Littérature clinique repérée par MEDLINE et EMBASE. Mots-clés: association triméthoprime-sulfaméthoxazole, Staphylococcus aureus.

RÉSUMÉ: Il a été conduit une évaluation des rapports de cas, des séries, et des études cliniques relatives à l'emploi du cotrimoxazole dans le traitement des infections sévères à S. aureus. Le seul essai à répartition aléatoire a conclu à la supériorité de la vancomycine par rapport au cotrimoxazole.

CONCLUSIONS: Dans certaines infections à faible charge bactérienne, en particulier dans les endocardites droites ou les infections ostéoarticulaires, le cotrimoxazole est susceptible de représenter une alternative à la vancomycine pour le traitement des infections sévères à S. aureus. D'autres études à répartition aléatoire devraient être conduites pour comparer cet agent à la vancomycine et au linézolide.

www.theannals.com, DOI 10.1345/aph.1D156


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
J. M. Entenza, A. Haldimann, M. Giddey, S. Lociuro, S. Hawser, and P. Moreillon
Efficacy of Iclaprim against Wild-Type and Thymidine Kinase-Deficient Methicillin-Resistant Staphylococcus aureus Isolates in an In Vitro Fibrin Clot Model
Antimicrob. Agents Chemother., September 1, 2009; 53(9): 3635 - 3641.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. A. Vickers, N. J. Potter, C. W. G. Fishwick, I. Chopra, and A. J. O'Neill
Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques
J. Antimicrob. Chemother., June 1, 2009; 63(6): 1112 - 1117.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. Oefner, M. Bandera, A. Haldimann, H. Laue, H. Schulz, S. Mukhija, S. Parisi, L. Weiss, S. Lociuro, and G. E. Dale
Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity
J. Antimicrob. Chemother., April 1, 2009; 63(4): 687 - 698.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
A. Wong-Beringer, L. K. Hidayat, and D. I. Hsu
Treatment of MRSA Infections With Older Molecules: A Reasonable Option for Investigation--Reply
Arch Intern Med, June 11, 2007; 167(11): 1208 - 1209.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
H. Hmouda, C. Ben Salem, K. Bouraoui, and L. Jemni
Treatment of MRSA Infections With Older Molecules: A Reasonable Option for Investigation
Arch Intern Med, June 11, 2007; 167(11): 1207 - 1208.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
H. Hmouda, C. Ben Salem, K. Bouraoui, and L. Jemni
Comment on: Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus
J. Antimicrob. Chemother., December 1, 2006; 58(6): 1307 - 1307.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
K. E Sabol, K. L Echevarria, and J. S Lewis II
Community-Associated Methicillin-Resistant Staphylococcus aureus: New Bug, Old Drugs
Ann. Pharmacother., June 1, 2006; 40(6): 1125 - 1133.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. Adra and K. R Lawrence
AUTHORS' REPLY:
Ann. Pharmacother., November 1, 2004; 38(11): 1971 - 1972.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
H. Hmouda and L. Jemni
Comment: trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections
Ann. Pharmacother., November 1, 2004; 38(11): 1970 - 1971.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adra, M.
Right arrow Articles by Lawrence, K. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adra, M.
Right arrow Articles by Lawrence, K. R

homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.